Clinical trials suggest that when the inflammation level is high initially (C-reactive protein >5 mg/dL), combined use of cytokine antagonists (e.g., TNF antagonist infliximab) and antidepressant therapy can improve the course of depression (Raison et al., 2013). The gene discussed is TNF; the disease is depressive disorder.